Pinilla-Ibarz, Javier

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

Villagra, A., Cheng, F., Wang, H.-W., Suarez, I., Glozak, M., Maurin, M., Nguyen, D., Wright, K. L., Atadja, P. W., Bhalla, K., et al. (2009) · Nature Immunology

T-cell and B-cell ImmunologyHistone Deacetylase Inhibitors Research

Cited by 455

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma

Dean, E. A., Mhaskar, R. S., Lu, H., Mousa, M. S., Krivenko, G. S., Lazaryan, A., Bachmeier, C. A., Chavez, J. C., Nishihori, T., Davila, M. L., et al. (2020) · Blood Advances

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 256

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

Knox, T., Sahakian, E., Banik, D., Hadley, M., Palmer, E., Noonepalle, S., Kim, J., Powers, J., Gracia-Hernandez, M., Oliveira, V., et al. (2019) · Scientific Reports

Cancer Immunotherapy and BiomarkersHistone Deacetylase Inhibitors Research

Cited by 170

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

Bewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., & Hazlehurst, L. A. (2008) · Molecular Cancer Therapeutics

Chronic Myeloid Leukemia TreatmentsProtein Tyrosine Phosphatases

Cited by 150

Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells

Cheng, F., Lienlaf, M., Perez-Villarroel, P., Wang, H.-W., Lee, C., Woan, K., Woods, D., Knox, T., Bergman, J., Pinilla-Ibarz, J., et al. (2014) · Molecular Immunology

Histone Deacetylase Inhibitors ResearchGenomics and Chromatin Dynamics

Cited by 140

A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs

Cheng, F., Lienlaf, M., Wang, H.-W., Perez-Villarroel, P., Lee, C., Woan, K., Rock-Klotz, J., Sahakian, E., Woods, D., Pinilla-Ibarz, J., et al. (2014) · The Journal of Immunology

Histone Deacetylase Inhibitors ResearchT-cell and B-cell Immunology

Cited by 106

T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model

Woods, D. M., Woan, K. V., Cheng, F., Sodré, A. L., Wang, D., Wu, Y., Wang, Z., Chen, J., Powers, J., Pinilla-Ibarz, J., et al. (2017) · Blood

T-cell and B-cell ImmunologyHistone Deacetylase Inhibitors Research

Cited by 74

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Yue, L., Sharma, V., Horvat, N. P., Akuffo, A. A., Beatty, M. S., Murdun, C., Colin, C., Billington, J. M. R., Goodheart, W. E., Sahakian, E., et al. (2020) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentHistone Deacetylase Inhibitors Research

Cited by 67

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

Mostofa, A., Distler, A., Meads, M. B., Sahakian, E., Powers, J. J., Achille, A., Noyes, D., Wright, G., Fang, B., Izumi, V., et al. (2021) · JCI Insight

Multiple Myeloma Research and TreatmentsHistone Deacetylase Inhibitors Research

Cited by 27